Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift
Kathy High's New Role:
Kathy High, co-founder of Spark Therapeutics, has become the CEO of US-Swiss biotech RhyGaze, focusing on eye disease drug development14.
Arvinas Leadership Changes:
Arvinas has seen several leadership changes, including the departure of Sean Cassidy, CPA, as Chief Financial Officer in February 2024, and the resignation of Bradley Margus from the company’s Board of Directors in December 202223.
RhyGaze Background:
RhyGaze is backed by GV and ARCH, indicating significant investment and support from these prominent venture capital firms1.
Kathy High's Background:
Kathy High is a renowned figure in gene therapy, having played a crucial role in the development of Luxturna, the first FDA-approved gene therapy for a rare form of inherited vision loss5.
Sources:
1. https://endpts.com/kathy-high-leads-gv-arch-backed-eye-disease-biotech-arvinas-commercial-exec-steps-down/
2. https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-chief-financial-officer-transition
3. https://ir.arvinas.com/static-files/8d983aee-d27f-4164-962d-9a0f92443de2
5. https://www.asgct.org/publications/kathy-high-md-giants-of-gene-therapy-podcast